AbbVie pays 49% premium for Apogee's eczema drug; CRH uses 60-day VWAP anchor for Arcosa. Both all-cash deals remove execution risk. Read the sector readthrough.
AbbVie agreed to buy Apogee Therapeutics for $10.9 billion and CRH agreed to acquire Arcosa for $8.5 billion, both all-cash deals announced Monday. The two acquisitions target different sectors but share a structural feature: cash eliminates the buyer's stock-price risk for sellers.
AbbVie will pay $135.11 per share for Apogee, a 49.49% premium to Friday's close. Apogee shares surged about 48% to $133.77 in premarket trading on Monday, meaning the stock sat only $1.34 below the cash offer. That narrow spread signals the market sees little execution risk. AbbVie shares rose about 1.3% on the news. The deal is AbbVie's largest buyout in more than five years and centers on zumilokibart, an antibody targeting IL-13 for atopic dermatitis. The pipeline bet positions AbbVie against Sanofi and Regeneron's Dupixent, the current leader in the space. ABBV stock page
CRH will acquire Arcosa at $150 per share in cash, representing an enterprise value of about $8.5 billion. CRH framed the price as a 25% premium to Arcosa's 60-day volume-weighted average price as of June 18. Because the anchor is a trailing average, the premium over Arcosa's most recent close was about 10.4%. Arcosa shares rose about 7.5% to $146 in premarket trading. CRH shares were roughly flat, suggesting the market saw the deal as fairly priced. The structure signals that CRH waited for a price it liked rather than chasing a run-up. CRH Appoints Ex-CF Industries CEO; Why Investors Are Watching
Both deals are all-cash, which removes share-price risk for sellers. Apogee holders get $135.11 and Arcosa holders $150 in cash, so neither payout depends on how the acquirer's stock trades before closing. That clean structure likely explains the tight spreads in both stocks.
AbbVie is paying up for an immunology pipeline. The $10.9 billion price is a 49.49% premium and AbbVie's largest deal in more than five years, centered on Apogee's lead eczema candidate zumilokibart. CRH's $8.5 billion acquisition expands its infrastructure presence, adding Arcosa's construction materials and utility structures to its portfolio. Both deals are expected to close in the second half of 2025, subject to regulatory approval.
The two deals led an otherwise quiet tape.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.